These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 27769353)
1. Erythropoiesis provides a BRD's eye view of BET protein function. Stonestrom AJ; Hsu SC; Werner MT; Blobel GA Drug Discov Today Technol; 2016 Mar; 19():23-28. PubMed ID: 27769353 [TBL] [Abstract][Full Text] [Related]
2. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity. Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503 [TBL] [Abstract][Full Text] [Related]
3. Suppression of T Ghosh S; Lora JM Drug Discov Today Technol; 2016 Mar; 19():39-44. PubMed ID: 27769356 [TBL] [Abstract][Full Text] [Related]
4. BET bromodomain inhibitors: a patent review. Garnier JM; Sharp PP; Burns CJ Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714 [TBL] [Abstract][Full Text] [Related]
5. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review. Yang CY; Qin C; Bai L; Wang S Drug Discov Today Technol; 2019 Apr; 31():43-51. PubMed ID: 31200858 [TBL] [Abstract][Full Text] [Related]
6. Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins. Raux B; Voitovich Y; Derviaux C; Lugari A; Rebuffet E; Milhas S; Priet S; Roux T; Trinquet E; Guillemot JC; Knapp S; Brunel JM; Fedorov AY; Collette Y; Roche P; Betzi S; Combes S; Morelli X J Med Chem; 2016 Feb; 59(4):1634-41. PubMed ID: 26735842 [TBL] [Abstract][Full Text] [Related]
7. Clinical trials for BET inhibitors run ahead of the science. Andrieu G; Belkina AC; Denis GV Drug Discov Today Technol; 2016 Mar; 19():45-50. PubMed ID: 27769357 [TBL] [Abstract][Full Text] [Related]
8. Targeting BET bromodomains for cancer treatment. Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433 [TBL] [Abstract][Full Text] [Related]
9. BET Bromodomain as a Target of Epigenetic Therapy. Noguchi-Yachide T Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788 [TBL] [Abstract][Full Text] [Related]
10. Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets. Situ Y; Liang Q; Zeng Z; Chen J; Shao Z; Xu Q; Lu X; Cui Y; Zhang J; Lu L; Deng L Front Endocrinol (Lausanne); 2023; 14():1089531. PubMed ID: 36793283 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938 [TBL] [Abstract][Full Text] [Related]
12. The conserved 12-amino acid stretch in the inter-bromodomain region of BET family proteins functions as a nuclear localization signal. Fukazawa H; Masumi A Biol Pharm Bull; 2012; 35(11):2064-8. PubMed ID: 22971749 [TBL] [Abstract][Full Text] [Related]
14. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries. Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791 [TBL] [Abstract][Full Text] [Related]
15. The Role of Bromodomain and Extraterminal Motif (BET) Proteins in Chromatin Structure. Hsu SC; Blobel GA Cold Spring Harb Symp Quant Biol; 2017; 82():37-43. PubMed ID: 29196562 [TBL] [Abstract][Full Text] [Related]
16. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors. Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064 [TBL] [Abstract][Full Text] [Related]
17. Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma. Xu L; Chen Y; Mayakonda A; Koh L; Chong YK; Buckley DL; Sandanaraj E; Lim SW; Lin RY; Ke XY; Huang ML; Chen J; Sun W; Wang LZ; Goh BC; Dinh HQ; Kappei D; Winter GE; Ding LW; Ang BT; Berman BP; Bradner JE; Tang C; Koeffler HP Proc Natl Acad Sci U S A; 2018 May; 115(22):E5086-E5095. PubMed ID: 29764999 [TBL] [Abstract][Full Text] [Related]
18. Potent and selective bivalent inhibitors of BET bromodomains. Waring MJ; Chen H; Rabow AA; Walker G; Bobby R; Boiko S; Bradbury RH; Callis R; Clark E; Dale I; Daniels DL; Dulak A; Flavell L; Holdgate G; Jowitt TA; Kikhney A; McAlister M; Méndez J; Ogg D; Patel J; Petteruti P; Robb GR; Robers MB; Saif S; Stratton N; Svergun DI; Wang W; Whittaker D; Wilson DM; Yao Y Nat Chem Biol; 2016 Dec; 12(12):1097-1104. PubMed ID: 27775716 [TBL] [Abstract][Full Text] [Related]
19. Phospho-BRD4: transcription plasticity and drug targeting. Chiang CM Drug Discov Today Technol; 2016 Mar; 19():17-22. PubMed ID: 27769352 [TBL] [Abstract][Full Text] [Related]
20. The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation. Zhang M; Wang B; Urabe G; Huang Y; Plutzky J; Kent KC; Guo LW Cell Signal; 2019 Sep; 61():20-29. PubMed ID: 31075399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]